Actinogen Medical
- Company typePublic
- Founded2013
- HeadquartersSydney, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Actinogen Medical firmographics
Firmographics- Name
- Actinogen Medical
- Legal name
- Actinogen Medical Limited
- Website
- https://actinogen.com.au
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Actinogen Medical industry classification
Industry- Product category
- Neurology Pharmaceuticals
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Actinogen Medical is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Actinogen Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical stage company. Xanamem is an investigational product not yet approved for commercial use. The company is preparing for potential future commercialization pending successful clinical trial outcomes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Actinogen Medical product offering
Product offeringCore offering
Actinogen Medical is developing Xanamem (emestedastat), a first-in-class, once-daily oral therapeutic that inhibits the 11β-HSD1 enzyme to control elevated cortisol production inside brain cells, targeting the hippocampus and frontal cortex. The investigational drug is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder (MDD), and Fragile X Syndrome, and is currently in Phase 2b/3 clinical trials.
Product overview
Actinogen Medical is developing Xanamem (emestedastat), a first-in-class oral therapeutic that controls elevated cortisol levels in the brain by inhibiting the 11β-HSD1 enzyme. The product is being developed as a treatment for Alzheimer's Disease, Major Depressive Disorder, and Fragile X Syndrome. The company operates across multiple clinical trials including the XanaMIA Phase 2b/3 pivotal trial in Alzheimer's disease, completed Phase 2a XanaCIDD trial in depression, and ongoing research in Fragile X Syndrome. Xanamem is an investigational drug not yet approved by any regulatory authority.
Differentiator
Problem solved
Functional benefit
Brands
- Xanamem® (emestedastat): Lead compound - an oral therapeutic designed to control brain cortisol levels by inhibiting the 11β-HSD1 enzyme, being developed for Alzheimer's disease, Major Depressive Disorder, and Fragile X Syndrome.
Products and services
- Xanamem (emestedastat) Xanamem is a first-in-class, once-daily oral therapeutic designed to control elevated cortisol levels in the brain by inhibiting the 11β-HSD1 enzyme. It is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder, and Fragile X Syndrome. The drug is an investigational product not yet approved by any regulatory authority and is currently being studied in the XanaMIA Phase 2b/3 pivotal Alzheimer's trial with 247 enrolled participants.
Quantifiable outcome
- Positive interim analysis outcome - DMC recommended trial continue without amendment
- +2 more outcomes
Companies that use Actinogen Medical
Customer profileSegments3 records
Ideal customer profiles4 records
Actinogen Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Actinogen Medical partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- Ernst & YoungminorExternal auditors providing independent financial statement audit services. Located at 11 Mounts Bay Road, Perth WA 6000.
- Automic Pty LtdminorShare registrars managing the company's share register on behalf of Actinogen. Provides shareholder services including inquiries and documentation.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Actinogen Medical competitors and assessment
Company assessmentDirect peers
- Anavex Life Sciences: Clinical-stage biotech developing small-molecule therapeutics (e.g., blarcamesine/ANAVEX 2-73) for Alzheimer's disease and other CNS indications including Rett syndrome. Directly comparable to Actinogen as a small-cap, CNS-focused, clinical-stage developer pursuing novel non-amyloid mechanisms in AD.
- Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease, a small molecule with a novel mechanism targeting altered filamin A. Closely comparable to Actinogen as a US-listed, small-cap biotech running pivotal-stage trials in AD with a differentiated non-amyloid approach.
- AC Immune: Swiss clinical-stage biotech developing therapeutics and diagnostics for neurodegenerative diseases including Alzheimer's. Highly comparable to Actinogen as a clinical-stage AD-focused company advancing multiple programs through partnerships with larger pharma.
- Sage Therapeutics: Clinical-stage CNS biotech developing novel small-molecule therapies (e.g., Zurzuvae/zuranolone for MDD/postpartum depression). Comparable to Actinogen as a small-molecule CNS specialist with depression as a lead indication and a first-in-class GABA receptor mechanism.
- Karuna Therapeutics: Clinical-stage CNS biotech developing xanomeline-trospium (Cobenfy) for schizophrenia and other CNS indications. Comparable to Actinogen as a small-molecule CNS specialist achieving pivotal-trial success and a major pharma acquisition (acquired by Bristol Myers Squibb for $14B in 2024).
Emerging players
- Prothena Corporation: Clinical-stage biotech developing protein-based therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable to Actinogen as a clinical-stage neuroscience specialist, though focused on biologics rather than small molecules.
- Cognition Therapeutics: Clinical-stage biotech developing CT1812 (zervimesine), a small-molecule sigma-2 receptor antagonist for Alzheimer's disease. Comparable to Actinogen as a small-cap clinical-stage AD biotech with a differentiated non-amyloid mechanism in pivotal trials.
Broad incumbents
- Eisai Co., Ltd. Japanese pharmaceutical company and co-developer of Leqembi (lecanemab), the leading approved anti-amyloid antibody for early Alzheimer's. Highly relevant incumbent peer and likely future competitor/partner for Actinogen given Eisai's deep AD commercial infrastructure.
- Biogen Inc. Large biotech co-developer and commercializer of Leqembi (lecanemab) for Alzheimer's and Aduhelm (aducanumab). Key incumbent establishing the AD market that Xanamem would enter; potential strategic partner or acquirer given Actinogen's CNS focus.
- Eli Lilly and Company: Major pharmaceutical company with Kisunla (donanemab) approved for early Alzheimer's and a deep neuroscience pipeline including depression assets. Most consequential incumbent peer that would shape commercial dynamics if Xanamem reaches market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Actinogen Medical social profiles
Digital presenceActinogen Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Actinogen Medical leadership team
Management profileNumber of profiles
Profiles12 records
Actinogen Medical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Actinogen Medical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Actinogen Medical
What does Actinogen Medical do?
Actinogen Medical is developing Xanamem (emestedastat), a first-in-class, once-daily oral therapeutic that inhibits the 11β-HSD1 enzyme to control elevated cortisol production inside brain cells, targeting the hippocampus and frontal cortex. The investigational drug is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder (MDD), and Fragile X Syndrome, and is currently in Phase 2b/3 clinical trials.
Is Actinogen Medical a public or private company?
Actinogen Medical is a public company. It is classified as public and is currently operating.
When was Actinogen Medical founded?
Actinogen Medical was founded in 2013. It employs 1 to 10 people.
Where is Actinogen Medical based?
Actinogen Medical is headquartered in Sydney, Australia, in the Oceania region.
How does Actinogen Medical make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Actinogen Medical's main competitors?
Direct peers on record are Anavex Life Sciences, Cassava Sciences, AC Immune, Sage Therapeutics and Karuna Therapeutics. Emerging players are Prothena Corporation and Cognition Therapeutics. Broad incumbents are Eisai Co., Ltd., Biogen Inc. and Eli Lilly and Company.
Does Actinogen Medical have an API?
No public API is recorded for Actinogen Medical.
What industry is Actinogen Medical in?
Actinogen Medical's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 54171 and its SIC code is 2836.